ITUS Corp. said it has entered into a Cooperative Research and Development Agreement with Moffitt Cancer Center, to advance toward human clinical testing, a Chimeric Antigen Receptor T-Cell technology aimed initially at ovarian cancer, and eventually additional solid tumors.
Love them or hate them, site visits have been a part of the culture of NCI-designated cancer centers for decades, shaping the process for admitting members to the elite club and influencing internal politics within institutions.
